Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Trifluridine is a thymidine-based nucleoside analog that incorporates into DNA, interfering with DNA synthesis and function. Tipiracil hydrochloride inhibits thymidine phosphorylase, preventing trifluridine degradation and increasing its systemic exposure.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Metastatic colorectal cancer (m CRC) previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.,Metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of therapy including a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
35 mg/m² orally twice daily on days 1-5 and 8-12 of each 28-day cycle. Maximum dose: 80 mg per dose.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
The terminal elimination half-life of trifluridine is approximately 1.4 to 2.1 hours. For tipiracil, the half-life is about 2.1 to 3.3 hours. The short half-lives necessitate twice-daily dosing to maintain therapeutic concentrations.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Trifluridine is primarily metabolized by thymidine phosphorylase to 5-(trifluoromethyl)uracil (inactive). Tipiracil is metabolized mainly via hepatic carboxylesterases and aldehyde oxidase, not significantly via CYP enzymes.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Trifluridine is primarily eliminated via metabolism and renal excretion. Approximately 29% of the trifluride dose is recovered in urine as trifluridine and its metabolites, with less than 3% as unchanged drug. Fecal excretion accounts for about 38% of the dose, mainly as metabolites. Tipiracil is predominantly excreted renally (about 55% as unchanged drug and metabolites) and fecally (about 19%).
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
Trifluridine: <1% bound to plasma proteins. Tipiracil: about 8% bound to plasma proteins.
82–88% bound to plasma proteins (primarily albumin).
Trifluridine: Vd/F is approximately 0.4 ± 0.1 L/kg, indicating distribution into total body water. Tipiracil: Vd/F is about 0.3 ± 0.1 L/kg.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Following oral administration of the combination tablet, trifluridine has an absolute bioavailability of approximately 57% (fasted). Tipiracil bioavailability is about 70% (fasted). Food may alter absorption.
Oral: 65–80% (median 73%)
For GFR 30-59 m L/min: reduce dose to 20 mg/m² twice daily. For GFR 15-29 m L/min: reduce dose to 15 mg/m² twice daily. Contraindicated if GFR <15 m L/min.
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 25 mg/m² twice daily. Child-Pugh C: not recommended.
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
Not established. Safety and efficacy in pediatric patients have not been studied.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
No specific dose adjustment recommended; monitor renal function and adjust based on renal impairment. Elderly patients may have increased risk of myelosuppression and infections.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
WARNING: NEUTROPENIA/THROMBOCYTOPENIA; AND GASTROINTESTINAL TOXICITY Neutropenia/Thrombocytopenia: Severe and life-threatening neutropenia and thrombocytopenia can occur. Obtain complete blood counts prior to each cycle and as clinically indicated. Withhold, reduce, or discontinue dosing for severe neutropenia or thrombocytopenia. Gastrointestinal Toxicity: Severe gastrointestinal toxicity including diarrhea, nausea, vomiting, and abdominal pain can occur. Withhold, reduce, or discontinue dosing for severe gastrointestinal toxicity.
None
Bone Marrow Suppression: May cause severe neutropenia, thrombocytopenia, and anemia. Monitor blood counts.,Gastrointestinal Toxicity: Severe diarrhea, nausea, vomiting, abdominal pain, and stomatitis. Manage with supportive care.,Renal Toxicity: Proteinuria, nephrotic syndrome. Monitor renal function.,Hepatic Toxicity: Elevations of liver enzymes and bilirubin. Monitor liver function.,Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of effective contraception and avoid breastfeeding.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
None reported in prescribing information. Use caution in patients with severe renal impairment (Cr Cl <30 m L/min) or severe hepatic impairment.
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
Take within 1 hour after a meal (breakfast and dinner) to reduce variability and improve tolerability. Avoid grapefruit or grapefruit juice? No established interaction; however, general caution due to potential CYP3A4 involvement? (minimal). High-fat meals may reduce peak concentration but do not significantly alter overall exposure; timing with meals is recommended not for efficacy but to mitigate gastrointestinal side effects.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
Trifluridine/tipiracil is embryotoxic and teratogenic in animal studies. In humans, avoid use during pregnancy; effective contraception required during treatment and for at least 6 months after last dose. First trimester: highest risk of major malformations; second and third trimesters: risk of fetal growth restriction and adverse neonatal outcomes.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
No human data on excretion in breast milk. Based on drug properties, likely present; advise against breastfeeding during treatment and for at least 1 day after last dose. M/P ratio unknown.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
No established dose adjustments for pregnancy; avoid use. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may alter exposure, but no data to guide adjustment.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
Tipiracil hydrochloride/trifluridine (Lonsurf) is a combination oral cytotoxic agent used for refractory metastatic colorectal cancer and gastric cancer. Trifluridine incorporates into DNA, inhibiting thymidylate synthase; tipiracil inhibits trifluridine degradation by thymidine phosphorylase. Administer within 1 hour after morning and evening meals to reduce variation in exposure. Avoid severe neutropenia by monitoring CBCs before and after each cycle; hold for ANC <500/mm³ or febrile neutropenia. Use antiemetics as needed; nausea/vomiting occur in ~50% of patients. Dose reduction recommended for severe myelosuppression, including thrombocytopenia and anemia. No strong CYP interactions; avoid concurrent use of UGT1A1 or thymidine phosphorylase inhibitors? (limited data). Consider growth factor support for prolonged neutropenia.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
Take each dose with a glass of water within 1 hour after breakfast and dinner; do not crush or chew tablets.,Swallow tablets whole; do not take if vomiting occurs after a dose—skip that dose and resume next scheduled dose.,Store at room temperature away from moisture and heat; keep bottle tightly closed.,Common side effects include nausea, vomiting, diarrhea, loss of appetite, fatigue, and low blood cell counts.,Contact healthcare provider immediately if fever, signs of infection (sore throat, cough), unusual bleeding/bruising, or severe tiredness occur.,Use effective contraception during treatment and for at least 6 months after the last dose for females and 3 months for males.,Avoid handling crushed or broken tablets; if contact occurs, wash skin thoroughly.,Do not breastfeed during treatment and for at least 1 day after last dose.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
"Tipiracil, a component of the combination chemotherapeutic agent Lonsurf (with trifluridine), inhibits thymidine phosphorylase and can also inhibit organic cation transporter 2 (OCT2). Pramipexole, a dopamine agonist used for Parkinson's disease and restless legs syndrome, is primarily eliminated renally via active tubular secretion mediated by OCT2. When coadministered, Tipiracil reduces the renal clearance of Pramipexole by inhibiting OCT2, leading to increased plasma concentrations of Pramipexole. This elevates the risk of dose-dependent adverse effects such as orthostatic hypotension, hallucinations, somnolence, and impulse control disorders."
"Tipiracil inhibits thymidine phosphorylase, which is involved in the metabolism of prazosin, leading to reduced clearance and increased systemic exposure of prazosin. This can result in enhanced alpha-adrenergic blockade, causing profound hypotension, dizziness, and syncope, especially during initial dosing or dose escalation."
"The serum concentration of Histamine can be increased when it is combined with Tipiracil."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE vs AGRYLIN, answered by our medical review team.
TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE is a Antineoplastic Agent that works by Trifluridine is a thymidine-based nucleoside analog that incorporates into DNA, interfering with DNA synthesis and function. Tipiracil hydrochloride inhibits thymidine phosphorylase, preventing trifluridine degradation and increasing its systemic exposure.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE is: 35 mg/m² orally twice daily on days 1-5 and 8-12 of each 28-day cycle. Maximum dose: 80 mg per dose.. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE is classified as Category C. Trifluridine/tipiracil is embryotoxic and teratogenic in animal studies. In humans, avoid use during pregnancy; effective contraception required during treatment and for at least 6. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.